Program
HDM2017
A development code.
Its studies are mostly in Colorectal Neoplasms, led by Huadong Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huadong Medicine | 22 open or running | phase 2since May 27, 2026 | Nov 24, 2025 | Dec 31, 2026phase 1 · NCT07274085 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 24, 2025First study: phase 1 study in Solid TumorsFirst studyNCT07274085 · 96 planned · China
- May 27, 2026Phase 2 study in Colorectal Cancer MetastaticPhase 2 reachedNCT07621159 · 120 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Solid TumorsNCT07274085
- Nov 1, 2027Primary completion: phase 2 study in Colorectal Cancer MetastaticNCT07621159
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07621159Colorectal Cancer Metastatic · China | 2 | Not yet recruiting | Nov 1, 2027 | 120 |
| NCT07274085Solid Tumors · China | 1 | Recruiting | Dec 31, 2026 | 96 |
How it is read
Names in the registry
- “HDM2017”, 2 entries
Codes read as this program: HDM2017.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.